Pubblicazioni

The impact of managed entry agreements on pharmaceutical prices  (2020)

Autori:
Gamba, Simona; Pertile, Paolo; Vogler, Sabine
Titolo:
The impact of managed entry agreements on pharmaceutical prices
Anno:
2020
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Formato:
Elettronico
Referee:
Nome rivista:
Health Economics
ISSN Rivista:
1057-9230
Intervallo pagine:
1-16
Parole chiave:
managed entry agreements; pharmaceutical prices; risk-sharing agreements
Breve descrizione dei contenuti:
Managed entry agreements (MEAs) have been used for several years, with the aim of curbing the growth of pharmaceutical expenditure and enhancing patient access to innovation. Yet, much remains to be understood about their economic implications. This paper studies the impact of MEAs on list prices, that is, prices before the deduction of any discount. Using a theoretical model, we show that, under most price setting regimes, the introduction of an MEA leads to a higher list price. This is confirmed by our empirical analysis of a sample of 156 medicines in six countries, providing a conservative estimate of the increase in price due to the MEA of 5.9%. A relevant policy implication is that payers may overestimate the financial gains that can be achieved through this  tool.
Id prodotto:
115452
Handle IRIS:
11562/1021580
ultima modifica:
18 novembre 2022
Citazione bibliografica:
Gamba, Simona; Pertile, Paolo; Vogler, Sabine, The impact of managed entry agreements on pharmaceutical prices «Health Economics»2020pp. 1-16

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro
Condividi